Wechselwirkungen · Tesavel
Tesavel 25 mg film-coated tablets Tesavel 50 mg film-coated tablets Tesavel 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-119784 · Präparat HOS-095021
In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin is CYP3A4, with contribution from CYP2C8. In patients with normal renal function, metabolism, including via CYP3A4, plays only a small role in the clearance of sitagliptin. Metabolism may play a more significant role in the elimination of sitagliptin in the setting of severe renal impairment or end-stage renal disease (ESRD). For this reason, it is possible that potent CYP3A4 inhibitors (i.e. ketoconazole, itraconazole, ritonavir, clarithromycin) could alter the pharmacokinetics of sitagliptin in patients with severe renal impairment or ESRD. The effect of potent CYP3A4 inhibitors in the setting of renal impairment has not been assessed in a clinical study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-01T12:05:00Z · SHA-256 8addcb407da8089454371dd22f7432a978ec735825167d238bfcd87dd57f7eb3 · Passage d5502dc23201c8c2241c94f1b89a7091a92573dfa05dfbff2c82abc8dd669b65 · Zeichen 189–959 im Abschnitt